Multicentre double-blind randomized placebo-controlled study “The Efficacy and Safety of Brillia for children in patients with attention deficit hyperactivity disorder (ADHD)”
Brillia for Сhildren significantly decreased the ADHD symptoms (by more than 50%) in 32% of patients with AHDH after 12 weeks of product use (assessed with ADHDRS-IV-Home Version scale)
*p<0.05 compared to placebo
#p<0.001 compared to baseline
Brillia for children has been found to improve attention by 31.7% after 12 weeks of product use (assessed with ADHDRS-IV-Home Version scale).
*p<0.01 compared to placebo
Brillia for children reduced ADHD symptoms severity by 36% after 12 weeks of product use (assessed with ADHDRS-IV-Home Version scale).